News from SGC

Posted on Tuesday 13th of February 2018

Two of the largest pharmaceutical companies in Brazil, Aché Laboratories and Eurofarma Laboratories, have partnered with the Brazilian Agency for Industrial Research and Innovation (Embrapii) to fund a medicinal chemistry project at the SGC lab at UNICAMP, Campinas, SP, Brazil.

Aché and Eurofarma will each provide R$2.4M funding over six years with R$3.6M from Embrapii to form the Embrapii “Centro de Química Medicinal de Inovação Aberta” (CQMED, English: “Centre for Open Innovation Medicinal Chemistry”).

Posted on Thursday 11th of January 2018

Kiev, Ukraine and Oxford, UK, 10 January 2018: Diamond Light Source (Diamond) and the Structural Genomic Consortium (SGC) Oxford announced today that Enamine, a chemical company and producer of novel chemical building blocks and screening libraries, will become a key supplier of poised fragment and analogue libraries to its XChem facility. Enamine will offer a new generation of the hit-finding library, Diamond-SGC-iNEXT (DSI) Poised Library to enable fast and productive fragment-based lead discovery(FBLD).

Posted on Monday 8th of January 2018

Congratulations to Professor Chas Bountra, Chief Scientist at the SGC Oxford and Professor of Translational Medicine at the Nuffield Department of Medicine and who has been appointed OBE for services to Translational Medical Research in the UK's New Year's Honours List 2018.

Posted on Monday 8th of January 2018

Professor Chas Bountra, Co-Director of the Oxford Martin Programme on Affordable Medicines and Chief Scientist at the Structural Genomics Consortium, explains why a new approach to drug discovery and development is needed to address the urgent need for new drugs.

Posted on Monday 11th of December 2017

Oxford researchers call for a new Pharmaceutical Commons

Pharmaceutical research and development (R & D) is one of the best examples of human ingenuity, attracting vast funding, employing brilliant minds, and deploying the most advanced technologies. Over the past century, it has enabled unprecedented advances for human health. Yet the pharmaceutical R & D system is struggling to keep up with society’s medical needs. High failure rates and prolonged research timelines for candidate drugs constitute a human tragedy, and have dramatically increased the cost of drug discovery over the last decades.  More and better medicines are desperately needed at a time of global...

more
Posted on Wednesday 6th of December 2017

                   

 

NeuroSGC created to increase volume and quality of cell assays for drug discovery

A new partnership between the Structural Genomics Consortium (SGC) and the Montreal Neurological Institute and Hospital (The Neuro) will use a unique open science framework to help scientists discover new targets for drug development for neurological diseases.

Posted on Monday 4th of December 2017

The Foundation for Food and Agriculture Research (FFAR), a nonprofit established in the 2014 Farm Bill with bipartisan congressional support, awarded a $1 million Seeding Solutions grant to University of California, Davis (UC Davis) to study the genetics of rice plants. Together with researchers at the University of North Carolina and collaborators, the team will develop and implement a chemistry-driven gene discovery approach to identify genes that modulate root traits. 

The FFAR grant has been matched with funding from the UC Davis Innovation Institute for Food and Health, the Structural Genomics Consortium, AgBiome, and Promega for a total $2.3 million investment.

Posted on Monday 4th of December 2017

Researchers at the University of North Carolina at Chapel Hill hub of the international Structural Genomics Consortium will partner with the University of California, Davis to study the genes of rice plants responsible for root growth. The scientists will create an open source database and lay the groundwork for developing new varieties of drought resistant crops.

Posted on Thursday 28th of September 2017

 

Osaka, Japan, San Diego, Calif., USA, and Stockholm, Sweden, September 28, 2017— Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), Karolinska Institutet (“KI”) and The Structural Genomics Consortium (“SGC”) today announced a combined pre-competitive and proprietary collaboration to discover and validate new potential intervention points for the treatment of Inflammatory Bowel Disease (IBD).

Posted on Friday 4th of August 2017

FREMONT, Calif., Aug. 3, 2017 /PRNewswire/ -- DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, in collaboration with the Structural Genomics Consortium (SGC) at the University of North Carolina at Chapel Hill today announced the completion of an important milestone and extension of their partnership to develop selective and potent chemical probes for the unexplored human kinome.

Pages

Subscribe to News from SGC
glqxz9283 sfy39587stf02 mnesdcuix8
sfy39587stf03